In Vitro Diagnostics Cardiology Neurology Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The IVD cardiology and neurology market covers a broad range of diagnostic products, including immunoassay instruments, clinical chemistry systems, molecular diagnostics, and point-of-care testing devices tailored for cardiac markers, coagulation parameters, and neurological biomarkers. In 2025, the global market is valued at approximately $17.22 billion, with projections to reach around $25 billion by 2030 at a compound annual growth rate of roughly 7.7%. This segment represents a critical subset of the broader in vitro diagnostics industry, which is expected to approach $157 billion by 2030.

• •Market valued at $17.22 billion in 2025, projected to reach $25.18 billion by 2030
• •Encompasses cardiac biomarkers, coagulation tests, neurological assays, and related diagnostic platforms
• •Part of a broader IVD industry estimated at over $109 billion for 2025

The increasing global prevalence of cardiovascular diseases and neurological conditions, including heart failure, coronary artery disease, stroke, Alzheimer's disease, and Parkinson's disease, is a fundamental driver of market expansion. An aging worldwide population amplifies the incidence of these chronic conditions, creating sustained demand for diagnostic testing in clinical laboratories, hospitals, and point-of-care settings. Technological innovations in high-sensitivity immunoassays, mass spectrometry, and next-generation molecular diagnostics are enabling earlier and more accurate disease detection, further fueling adoption.

• •Rising incidence of cardiovascular and neurological diseases linked to aging demographics and lifestyle factors
• •Advances in high-sensitivity cardiac biomarkers and molecular diagnostic technologies improving test accuracy
• •Growing emphasis on early diagnosis and preventive healthcare strategies

The market is segmented by product type, technology, end user, and geography. Product categories include reagents and consumables, instruments, and software and services, with reagents representing the largest revenue share. Geographically, North America currently holds the dominant market position due to advanced healthcare infrastructure, high disease prevalence, and strong adoption of innovative diagnostic technologies. The Asia-Pacific region is expected to grow at the fastest pace, driven by improving healthcare access, rising disposable incomes, and growing awareness of advanced diagnostic options.

• •North America leads in market share, followed by Europe and the rapidly expanding Asia-Pacific region
• •Reagents and consumables constitute the largest product segment, while instruments and software services show strong growth
• •Hospitals and diagnostic laboratories remain the primary end-user segments

What are the recent trends and outlook?

The market is moving toward greater integration of artificial intelligence and automation in diagnostic workflows, enabling faster turnaround times and improved clinical decision support. Personalized medicine and companion diagnostics are gaining prominence, with biomarker-based tests increasingly used to tailor treatment strategies for individual patients. The growing shift toward decentralized testing through point-of-care and home-based diagnostics is expected to reshape the competitive dynamics of the market over the forecast period.

• •AI-powered diagnostic platforms and laboratory automation systems are accelerating adoption of advanced testing solutions
• •Point-of-care and decentralized testing models expanding access to cardiac and neurological diagnostics outside traditional lab settings
• •Long-term market outlook remains positive, supported by ongoing R&D investment and unmet clinical needs